On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
|Articles|May 11, 2018
- Vol. 64 No. 05
- Volume 64
- Issue 5
Maternal Mortality Resources - Hypertensive Disorders
Advertisement
A collection of standards, guidelines, tools and articles for the OB caring for pregnant patients with hypertensive disorders.
Having trouble viewing?
Trouble viewing this PDF?
Once you access the file, position your mouse over the top middle for a toolbar:
Articles in this issue
over 8 years ago
Shoulder dystocia and brachial plexus injuryover 8 years ago
Hepatitis C in pregnancy: Screening, treatment, and managementover 8 years ago
Zika news, cautions and precautions for 2018over 8 years ago
Nitrous oxide’s revival in childbirthover 8 years ago
Risks and benefits of hormonal contraceptionNewsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
SubscribeAdvertisement
Related to this article
Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.
SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.
Anti-CGRP antibody exposure in early pregnancy was linked to higher spontaneous abortion risk; propranolol was not.
In the debut episode of Missed & Dismissed, Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, talks with Charis Chambers, MD, about PCOS, the push to rename it PMOS, and why diagnostic delays so often begin in adolescence.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Pritelivir healed all HSV lesions by day 28 in 63% of immunocompromised adults vs 34% with comparators.
Advertisement
Advertisement